Cytiva

Articles

Purification of Antibody Therapeutics - Approach for Diversified Pipeline

Antibody therapeutics are the largest class of biotherapeutics. Over the years, development beyond traditional monoclonal antibodies (mAbs) has increased. Today, we see multispecific and bispecific antibodies, antibody fragments, and antibody drug conjugates in the development pipeline. Manufacturing platform approaches conveniently used for many traditional mAbs are being adopted or tweaked to fit the respective molecule. In this ebook, you will learn about considerations and tips for developing chromatography protocols for antibody variants.

Test Page - QbD - whitepaper

This white paper summarizes information around chromatography resin variability, providing support for developing robust purification bioprocesses.

QbD - understanding sources of process variability

This white paper summarizes information around chromatography resin variability, providing support for developing robust purification bioprocesses.

Q&A: Oligonucleotide Synthesis in Process Development and Scale-Up

Give a quick overview of the oligonucleotide market, what is happening. Cover the typical challenges with oligonucleotide synthesis in the process development phase and solutions for those. Key considerations when scaling up oligonucleotide synthesis

Using Mechanistic Modelling in your Process Development of Advanced Therapeutics

Innovation has brought about a diversification of therapeutics molecules. In this discovery interview we will explore what mechanistic modelling is and how you can use it to develop these diverse therapeutics and what challenges this brings to the future of your process development.

Top questions answered on challenging HCP assays

Cytiva experts answer your top questions about challenging host cell protein assays to improve risk mitigation.